REMS Abuse And Antitrust Injury: Round Peg, Square Hole
In recent years, a small crop of complaints have alleged that brand pharmaceutical companies take advantage of distribution restrictions in U.S. Food and Drug Administration-imposed "risk evaluation and mitigation strategy" —...To view the full article, register now.
Already a subscriber? Click here to view full article